广汽集团(601238) - 2024 Q4 - 年度业绩预告
2025-01-11 00:00
| A股代码: 601238 | | --- | | H股代码:02238 | H股代码:02238 H 股简称:广汽集团 A股代码:601238 A股简称:广汽集团 公告编号:临2025-004 广州汽车集团股份有限公司 2024 年年度业绩预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 经初步测算,本公司预计 2024 年度实现归属于母公司所有者的净利润 与上年同期相比,将减少 322,890 万元到 362,890 万元,同比减少 72.91% 到 81.94%。 一、本期业绩预告情况 (一)业绩预告期间:2024 年 1 月 1 日至 2024 年 12 月 31 日 (二)业绩预告情况 经财务部门初步测算,预计 2024 年度实现归属于母公司所有者的净利润为 80,000 万元到 120,000 万元,与上年同期相比,将减少 322,890 万元到 362,890 万元,同比减少 72.91%到 81.94%。 预计 2024 年度实现归属于母公司所有者的扣除非经常性损益的净利润为- 330 ...
Richardson Electronics(RELL) - 2025 Q2 - Quarterly Report
2025-01-10 22:54
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from To Commission File Number: 0-12906 RICHARDSON ELECTRONICS, LTD. (Exact name of registrant as specified in its charter) (State or other jurisdiction of inco ...
Pure Cycle(PCYO) - 2025 Q1 - Quarterly Results
2025-01-10 22:45
Exhibit 99.1 Pure Cycle Announces Financial Results For the Three Months Ended November 30, 2024 DENVER, CO / ACCESSWIRE / January 8, 2025 – Pure Cycle Corporation (NASDAQ Capital Market: PCYO) announced its financial results for the three months ended November 30, 2024. Pure Cycle reported $3.9 million of net income for the three months ended November 30, 2024, which is a 91% increase compared to 2023, and marks our twenty-second consecutive fiscal quarter with positive net income. Pure Cycle reported $0.1 ...
Accolade(ACCD) - 2025 Q3 - Quarterly Report
2025-01-10 22:30
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________ FORM 10-Q ______________________________________________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39348 A ...
Y-mAbs(YMAB) - 2024 Q4 - Annual Results
2025-01-10 22:27
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 6, 2025 Y-MABS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38650 47-4619612 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 230 Park Avenue Suite 3350 New York, New Yo ...
NeuroOne Medical Technologies (NMTC) - 2025 Q1 - Quarterly Results
2025-01-10 22:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 7599 Anagram Dr., Eden Prairie, MN 55344 (Add ...
First Interstate BancSystem(FIBK) - 2024 Q4 - Annual Results
2025-01-10 21:53
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 ------------------------------ FORM 8-K ------------------------------ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 3, 2025 ------------------------------ FIRST INTERSTATE BANCSYSTEM, INC. (Exact name of registrant as specified in its charter) ------------------------------ | | | (State or other jurisdiction of incorporation or organization ...
The Greenbrier panies(GBX) - 2025 Q1 - Quarterly Report
2025-01-10 21:45
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended November 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ______ to ______ Commission File No. 1-13146 THE GREENBRIER COMPANIES, INC. (Exact name of registrant as specified in its charter) One Centerpointe Drive, Suite 200, Lak ...
UniFirst(UNF) - 2025 Q1 - Quarterly Report
2025-01-10 21:36
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Massachusetts 04-2103460 (State or Other Jurisdiction of Incorporation or Organization) 68 Jonspin Road, Wilmington, MA 01887 (Address of Principal Executive Offices) (Zip Code) (I.R.S. Employer Identification No.) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol | Name of each exchange on ...
4D Molecular Therapeutics(FDMT) - 2024 Q4 - Annual Results
2025-01-10 21:36
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) 5858 HORTON STREET #455 EMERYVILLE, California 94608 (Address of Principal Executive Offices) (Zip Code) (Commissio ...